Back to discover
Drug

Fluticasone propionate

Established medicine
ClassGlucocorticoid receptor agonistResearchActive indication expansion
Also known as Advair, AirDuo, Aller-Flo, Armonair+12 more

Advair, AirDuo, Aller-Flo, Armonair, Beser, Clarispray, Cutivate, Dymista, Flonase, Flonase Sensimist, Flovent, Fluticare, Fluticasone, Nasopro 24, Wixela, Xhance.

RxNorm50121ChEMBLCHEMBL1473ATCD07AC17ATCR01AD08ATCR03BA05ATCR01AD58UNIIO2GMZ0LF5W
3
Research papers
7
Active clinical trials
Glucocorticoid receptor
Primary target
15
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Evaluation Of The Adjunctive Effects Of Moxibustion In The Treatment Of Cold-Syndrome Allergic Rhinitis

Clinical trial2026-08-30Primary completion · ClinicalTrials.gov

Label change: FLUTICASONE PROPIONATE (ANDA217088)

Regulatory2026-08-25FDA

Label change: FLUTICASONE PROPIONATE (ANDA217088)

Regulatory2026-08-25FDA

Approval: FLUTICASONE PROPIONATE (ANDA219232)

Regulatory2026-08-18FDA

Approval: FLUTICASONE PROPIONATE AND SALMETEROL (ANDA213087)

Regulatory2026-07-27FDA

A Proof-of-Concept Study of a Novel Method for Removal of Residual Oropharyngeal Inhaled Corticosteroid Deposits in Asthma

Clinical trial2026-07-01Results expected Q2 2027 · ClinicalTrials.gov

An Open-Label, Phase 2 Study to Evaluate the Activity of Belumosudil in Subjects With New Onset and Incipient Bronchiolitis Obliterans Syndrome Following Allogeneic Hematopoietic Cell Transplantation

Clinical trial2026-06-10Results expected Q2 2027 · ClinicalTrials.gov

Biologics and Blistering - Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation Through Suction Blistering

Clinical trial2026-06-09Results expected Q1 2027 · ClinicalTrials.gov

A Randomized, Open-labelled Bronchoscopy Study to Assess the Effects of Inhaled Corticosteroids (ICS) on Adult Healthy Volunteers

Clinical trial2026-03-02Results expected Q4 2026 · ClinicalTrials.gov

Comparison of systemic pharmacodynamic effects of two combination pressurized metered dose inhalers that deliver salmeterol and fluticasone propionate.

Research2017-08-01British journal of clinical pharmacology

Treatment effects of low-dose theophylline combined with an inhaled corticosteroid in COPD.

Research2010-03-18Chest

Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids.

Research2010-03-02The New England journal of medicine

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Fluticasone propionate
Aliases & brands
AdvairAirDuoAller-FloArmonairBeserClarisprayCutivateDymistaFlonaseFlonase SensimistFloventFluticareFluticasoneNasopro 24WixelaXhance
RxNorm CUI
50121
ChEMBL ID
CHEMBL1473
ATC codes
D07AC17R01AD08R03BA05R01AD58
UNII
O2GMZ0LF5W
Primary mechanism
Glucocorticoid receptor agonist
Regulatory jurisdictions
fda

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Glucocorticoid receptor
NR3C1 · P04150
AGONISTGlucocorticoid receptor agonist

Regulatory timeline

15 events

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2014-07-23
Latest approval
2026-08-18
Authorities
FDA
Total events
15
fdaU.S. Food and Drug Administration· 15 events
2026-08-25Label change
Label change: FLUTICASONE PROPIONATE (ANDA217088)
Evidence ↗
2026-08-25Label change
Label change: FLUTICASONE PROPIONATE (ANDA217088)
Evidence ↗
2026-08-18Approval
Approval: FLUTICASONE PROPIONATE (ANDA219232)
Evidence ↗

Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).

Clinical trials

164 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
164
registered trials across all phases
LATEST COMPLETION 2024
7
Active studies
3
Recruiting
111
Late-stage (III+)
129
Completed
28
Discontinued
PHASE DISTRIBUTIONn = 164
Early Phase 11Phase 117Phase 235Phase 2 / 35Phase 344Phase 447Phase N / A15

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

A Proof-of-Concept Study of a Novel Method for Removal of Residual Oropharyngeal Inhaled Corticosteroid Deposits in Asthma

Not yet recruitingPH IVUniversity of Wisconsin, Madisonn=202027

A Randomized, Open-labelled Bronchoscopy Study to Assess the Effects of Inhaled Corticosteroids (ICS) on Adult Healthy Volunteers

Active, not recruitingPH IVUniversity Hospitals, Leicestern=302026

Effectiveness of Cycling of Topical Steroid Therapy in Maintaining Clinical and Histologic Remission in Eosinophilic Esophagitis

CompletedPH IVUniversity Hospitals Cleveland Medical Centern=232023

Randomized Controlled Trial Comparing Fluticasone Plus Omeprazole With Fluticasone Alone for Eosinophilic Esophagitis

Unknown statusPH IVClaire Danielsn=1002022

A Single-Center, Randomized, Double-Masked, Parallel Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Flonase® Allergy Relief in Reducing Ocular Itching in Subjects With Allergic Conjunctivitis

CompletedPH IVAndover Research Eye Instituten=612022

Recent completions

Trials that read out recently, adding to the completed evidence base.

ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications

CompletedPH IIIKey trialSusanna Naggie, MDn=10,9562024

Effectiveness of Cycling of Topical Steroid Therapy in Maintaining Clinical and Histologic Remission in Eosinophilic Esophagitis

CompletedPH IVUniversity Hospitals Cleveland Medical Centern=232023

A Single-Center, Randomized, Double-Masked, Parallel Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Flonase® Allergy Relief in Reducing Ocular Itching in Subjects With Allergic Conjunctivitis

CompletedPH IVAndover Research Eye Instituten=612022

ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications

CompletedPH IIIKey trialSusanna Naggie, MDn=1,4072022

Prospective, Comparative, Double-blind, Parallel, Multicentric, Randomized Study Between Two Brands of Fluticasone Propionate Nasal Topic in The Control of Perene Allergic Rhinithis Symptoms

CompletedPH IIILibbs Farmacêutica LTDAn=5662020

Evaluating Factors Involved in Dymista's Superior Clinical Efficacy to Fluticasone Propionate in the Treatment of Seasonal Allergic Rhinitis

CompletedPH IVUniversity of Chicagon=222020

Research activity

3 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20102017
Journals, researchers & institutions
Top journals
  • British journal of clinical pharmacology1
  • Chest1
  • The New England journal of medicine1
Leading researchers
  • Adcock IM1
  • Bacharier LB1
  • Barnes PJ1
  • Boehmer SJ1
  • Chalmers D1
  • Covar RA1
  • Durham AL1
  • Efthimiou J1
Leading institutions
free-text, unnormalised
  • Clinical and Biostatistics1
  • Clinical Programme Management1
  • Clinical Research1
  • National Heart and Lung Institute1
  • Quotient Clinical1
  • University of Wisconsin School of Medicine and Public Health1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.